DIAGNOS Announces Private Placement

Group 1 - The core announcement is about Diagnos Inc. conducting a non-brokered private placement of 10 units at a price of $10,000 per unit, aiming for gross proceeds of $100,000 [1][2] - Each unit consists of an unsecured convertible debenture with a 12-month term and an annual interest rate of 10%, which can be converted into common shares at a price of $0.28 per share [1][2] - Additionally, each warrant allows the holder to purchase one share at a price of $0.40 per share during the term [2] Group 2 - The proceeds from the private placement will primarily fund product development and commercialization of AI-based screening services, along with general and administrative expenses [2] - A director of the corporation has committed to subscribe for all units in the private placement [2] - All securities issued will be subject to a 4-month statutory hold period and require approval from the TSX Venture Exchange [3] Group 3 - Diagnos Inc. is focused on early detection of critical eye-related health issues using advanced AI technology to enhance diagnostic accuracy and improve patient outcomes globally [4]